soul trial oral semaglutide cardiovascular outcomes 2024 π§Ώ is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM Impact of Oral Semaglutide on
Description
Early recognition saves lives
Black Friday Starts NOW
The biotech crashed 53% in the aftermath of the readout.
If the doctor approves, your medication will be shipped to you
Recently, SGLT2i and GLP1- RAs have emerged as potential therapeutic tools preventing the transition from acute to chronic kidney disease due to their efficacy in preserving renal function
